hdl c levels and non abca1 specific cholesterol efflux capacity after cetp inhibition or placebo n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo PowerPoint Presentation
Download Presentation
HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo

Loading in 2 Seconds...

play fullscreen
1 / 1

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo - PowerPoint PPT Presentation


  • 78 Views
  • Uploaded on

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo. 70. 60. placebo. 30. dalcetrapib. 50. HDL-cholesterol (mg/dL). 20. % change from baseline in non-ABCA1-specific cholesterol efflux. 40. placebo. dalcetrapib. 30. 10. 20. 0. 0. 4. 8.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo' - marisa


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
hdl c levels and non abca1 specific cholesterol efflux capacity after cetp inhibition or placebo
HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo

70

60

placebo

30

dalcetrapib

50

HDL-cholesterol (mg/dL)

20

% change from baseline in non-ABCA1-specific cholesterol efflux

40

placebo

dalcetrapib

30

10

20

0

0

4

8

12

20

0

4

12

20

week

week

Ray et al., Eur Heart J 2014